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Long noncodingRNAs (lncRNAs) are often expressed
in a development-specific manner, yet little is known
about their roles in lineage commitment. Here,
we identified Braveheart (Bvht), a heart-associated
lncRNA in mouse. Using multiple embryonic stem
cell (ESC) differentiation strategies, we show that
Bvht is required forprogressionof nascentmesoderm
toward a cardiac fate. We find that Bvht is necessary
for activation of a core cardiovascular gene network
and functions upstream of mesoderm posterior 1
(MesP1), a master regulator of a commonmultipotent
cardiovascular progenitor. We also show that Bvht
interacts with SUZ12, a component of polycomb-
repressive complex 2 (PRC2), during cardiomyocyte
differentiation, suggesting that Bvhtmediates epige-
netic regulation of cardiac commitment. Finally, we
demonstrate a role for Bvht in maintaining cardiac
fate in neonatal cardiomyocytes. Together, our work
provides evidence for a long noncoding RNA with
critical roles in the establishment of the cardiovas-
cular lineage during mammalian development.
INTRODUCTION
The heart is the first organ to function during vertebrate embryo-
genesis. In mammals, cardiogenesis involves the diversifica-
tion of pluripotent cells in the embryo toward mesodermal and
cardiac cell types, including cardiomyocytes (Kattman et al.,
2007). Coordination of this process depends on precise control570 Cell 152, 570–583, January 31, 2013 ª2013 Elsevier Inc.of gene expression patterns, and disruption of transcriptional
networks that govern cardiac commitment underlies congenital
heart disease (CHD) (Bruneau, 2008; Srivastava, 2006). Notably,
cardiovascular disease and aging lead to a progressive loss of
cardiomyocytes, yet the adult mammalian heart has limited
regenerative capacity (Mercola et al., 2011; Steinhauser and
Lee, 2011). The derivation of cardiomyocytes from pluripotent
stem cells in vitro is a potentially promising strategy for regener-
ative therapy, but the inability to generate sufficient quantities of
high-quality cardiac cells has been a limitation to realizing this
potential. Thus, knowledge of the molecular switches that con-
trol cardiac commitment is critical to achieve a better under-
standing of heart development and to design better approaches
for treatment of cardiac-related diseases.
Development of the cardiovascular system, including the
heart, is a multistep process that is coordinated by a network
of transcription factors (Murry and Keller, 2008; Olson, 2006).
For example, the transcription factor mesoderm posterior 1
(MESP1) is critical for the establishment of a multipotent car-
diovascular progenitor population during gastrulation (Bondue
et al., 2008; Lindsley et al., 2008).MesP1 is transiently expressed
in the nascent mesoderm, and its expression marks those
cells destined to give rise to the cardiovascular lineage (Saga
et al., 1996, 1999, 2000). Consistent with this idea, forced
expression of MesP1 during embryonic stem cell (ESC) dif-
ferentiation leads to an increase in the cardiogenic population
(Bondue et al., 2008). MESP1 regulates a core network of tran-
scription factors, including many regulators of heart develop-
ment as well as genes with roles in epithelial-to-mesenchymal
transition (EMT) such as Snai and Twist (Bondue et al., 2008;
Lindsley et al., 2008). EMT is critical for gastrulation and mor-
phogenetic movements during organogenesis, including heart
formation (Lim and Thiery, 2012; von Gise and Pu, 2012). Thus,
identifying additional factors that promote a mesoderm-to-
cardiovascular transition may provide mechanistic insights into
the regulation of heart development.
Long noncoding RNAs (lncRNAs) are broadly classified as
transcripts longer than 200 nucleotides that are 50 capped and
polyadenylated like most mRNAs, yet this class of transcripts
has limited coding potential. lncRNAs function in a wide range
of processes and can regulate gene expression by diversemech-
anisms (Hu et al., 2012; Mercer et al., 2009; Ponting et al., 2009;
Rinn and Chang, 2012). Though thousands of lncRNAs have
been identified across eukaryotes, many are species specific
and appear less conserved than protein-coding genes (Cabili
et al., 2011; Derrien et al., 2012; Ulitsky et al., 2011). Importantly,
lncRNAs are differentially expressed across tissues, suggesting
that they regulate lineage commitment. Consistent with this
idea, loss of function of two lncRNAs in zebrafish embryos, cy-
rano and megamind, resulted in various developmental defects
(Ulitsky et al., 2011).Moreover, HOTTIPplays a role in limb forma-
tion (Wang et al., 2011), whereas other lncRNAs function to
promote or suppress somatic differentiation (Hu et al., 2011;
Kretz et al., 2012a, 2012b). Furthermore, depletion of a subset
of lncRNAs in mouse ESCs led to upregulation of global lineage
programs (Guttman et al., 2011). Despite these promising find-
ings, our knowledge of lncRNAs that function in lineage commit-
ment is limited to only a few examples, and a detailed under-
standing of the genetic pathways that they regulate is lacking.
Here, we report the identification of AK143260, which we
named Braveheart (Bvht), a lncRNA in mouse that is necessary
for cardiovascular lineage commitment. Using multiple ESC
differentiation strategies, we found that Bvht was necessary for
activation of a core gene regulatory network that included
key cardiac transcription factors (e.g., MesP1, Gata4, Hand1,
Hand2, Nkx2.5, and Tbx5) and EMT genes (e.g., Snai and Twist).
Further analysis revealed a significant overlap between the
genes regulated by Bvht and MESP1, a master regulator of car-
diovascular potential. Moreover, forced expression of MesP1
rescued the Bvht depletion phenotype, indicating that these
two factors function in a similar genetic pathway. We show
that Bvht interacts with SUZ12, a core component of poly-
comb-repressive complex 2 (PRC2), suggesting that this inter-
action may be critical for epigenetic regulation of network genes.
We also demonstrate that Bvht is necessary for maintenance of
cardiac fate in ex vivo neonatal cardiomyocytes. Together, these
results indicate that Bvht functions to regulate gene expression
programs that promote commitment toward the cardiovascular
lineage. More broadly, our work identifies a potential additional
pathway for regulation of heart development and suggests that
lncRNAs represent targets that can be exploited for efficient
generation of stem-cell-derived cardiac cells.
RESULTS
Identification of Candidate lncRNAs in the Cardiac
Lineage
lncRNAs exhibit distinct expression patterns across tissues (Der-
rien et al., 2012; Dinger et al., 2008); however, we have limited
knowledge of their precise molecular roles during mammalian
development. We reasoned that lncRNAs whose expressionbecomes restricted to specific cell types during ESC differentia-
tion represent candidate regulators of lineage commitment. We
analyzed lncRNA expression asmeasured by RNA-seq inmouse
ESCs as well as in differentiated tissues representing the three
germ layers (Mortazavi et al., 2008). We identified 47 candidates
that displayed high expression in ESCs and lower median
expression across the tissues examined (Figure 1A and Table
S1 available online). To identify lncRNAs with potential roles in
cardiac commitment, we next evaluated the expression of indi-
vidual candidates in each tissue, including the heart (Figure 1B).
We focused on AK143260 located on mouse chromosome
18:61,799,307–61,807,126 (+ strand, mm9) because it displayed
higher expression in the heart relative to the other tissues exam-
ined in this study. Thus, we named the candidate Braveheart
(Bvht).
lncRNAs are a newly emerging class of RNA, and their status
as noncoding transcripts from genome annotations requires
independent validation. We determined by rapid amplification
of cDNA ends (RACE) that Bvht is an 590 nucleotide transcript
comprising three exons, consistent with our RNA-seq and
northern analysis in ESCs (Figures 1C and 1D). We also detected
an isoform that lacked the first exon (50 bases), which repre-
sented only a minor fraction of the total transcript as determined
by RACE. Cell fractionation followed by quantitative RT-PCR
(qRT-PCR) showed that 33% of the spliced Bvht transcript
resides in the nucleus (Figure S1A). Notably, HOTAIR, a lncRNA
with nuclear function, is also distributed across both cell com-
partments in human fibroblasts (Khalil et al., 2009). Though
Bvht harbors short open reading frames (ORFs) (the two largest
are 48 and 74 aa), ORFs of this size would be expected by
chance in a transcript of this length (Figure S1B). Consistent
with the recent finding that lncRNAs are rarely translated in
human cells (Ba´nfai et al., 2012), we found no evidence of
active translation or production of a protein product from Bvht
(Figures S1C–S1F and Supplemental Information). Moreover,
sequence homology searches revealed no clear orthologous
Bvht sequence or transcripts in syntenic regions of the human
or rat genomes, consistent with the idea that lncRNAs are less
conserved than protein-coding genes (Cabili et al., 2011; Derrien
et al., 2012). For example, analysis of RNA-seq data from human
and rat heart, a tissue in mouse that displays strong expression
of bothBvht and the conserved neighboringmiR143/145 cluster,
revealed robust expression of the pri-miRNA in human and rat,
whereas transcripts from the Bvht region were not detected (Fig-
ure 1E). Thus, Bvht appears to be a mouse-specific lncRNA and
is an example of a recently evolved rapid gain-of-function non-
coding transcript.
Braveheart Is Necessary for Proper ESC Differentiation
To dissect the function ofBvht in lineage commitment, we gener-
ated mouse embryonic stem cell (mESC) lines that stably ex-
pressed short hairpin RNAs (shRNA) directed against either
exon 2 or 3. We observed significant depletion (80%) of the
transcript in ESCs as measured by qRT-PCR and northern anal-
ysis (Figures 2A and 1D). Notably, Bvht depletion in ESCs did not
affect colony morphology, expression of pluripotency markers,
the fraction of apoptotic cells, or cell-cycle kinetics compared
to control cells harboring a nontargeting hairpin (Figures 2BCell 152, 570–583, January 31, 2013 ª2013 Elsevier Inc. 571
Figure 1. Identification AK143260 as a Candidate Heart-Associated lncRNA
(A) Differential expression enrichment score calculated from RNA-seq data from biological replicates of two independent mESC lines and adult tissues (brain,
liver, and skeletal muscle) representing the three germ layers. Stars represent the position of three example candidates and their respective GenBank accession
numbers. The y axis represents the number of lncRNAs with a particular differential expression enrichment, as denoted by each bar.
(B) Transcriptome analysis in a broader range of tissues showed that AK143260 was predominantly expressed in ESCs and in heart.
(C) Depiction of transcript structure as defined by 50 and 30 RACE (bottom) was consistent with RNA sequencing reads in ESCs (top).
(D) Northern analysis using a full-length probe for AK143260 confirms the predicted size of the transcript (590 nucleotides) and shows reduced levels upon
shRNA-mediated depletion in mESCs.
(E) RNA sequencing reads from rat adult heart and human adult heart samples showed no evidence of a transcript expressed in a location syntenic to AK143260.
Arrows mark direction of transcription.
See also Figure S1 and Table S1.
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Figure 2. Bvht Is Required for Proper ESC Differentiation
(A) Targeting of AK143260 (Bvht) in mESCs by two independent hairpins directed to either exon 2 or 3 led to significant depletion of the transcript as measured by
qRT-PCR. Experiments were performed in triplicate, and error bars represent SD within one representative experiment.
(B) Bvht depletion does not affect colony morphology and OCT4 staining in ESCs. Scale bar, 100 mm.
(C) Percentage of spontaneously contracting EBs determined at days 8 and 11 of differentiation (n > 100 per time point). Bvht-depleted EBs showed a significant
decrease in contracting EBs compared to controls. The number of resulting EBs was similar in each experiment. Experiments were performed in triplicate, and
error bars represent SD.
(D) Expression of cardiac Troponin T (cTnT) measured by qRT-PCR at representative time points shows decreased levels in Bvht-depleted EBs. Error bars
represent SD of a triplicate set of experiments.
(E) Antibody staining of paraffin-embedded sections of day 12 EBs showed decreased cTNT abundance in Bvht-depleted compared to controls. Scale
bar, 300 mm.
(F)Bvht-depleted EBs can form tissues representative of all three germ layers, including gut-like epithelium (endoderm), cartilage (mesoderm), and neuroepithelial
rosettes (ectoderm) as represented in hematoxylin and eosin (H&E)-stained EB sections. Scale bar, 100 mm. **p < 0.01 by two-tailed Student’s t test.
See also Figure S2 and Table S2.and S2A–S2C). Thus, Bvht is not required to maintain ESC self-
renewal.
ESCs have the capacity to differentiate into derivatives of the
three germ layers, including cardiac cell types. We next inducedBvht-depleted ESCs to differentiate by allowing cells to aggre-
gate into embryoid bodies (EBs). Given its expression in
the heart, we investigated whether Bvht-depleted cells could
form cardiac tissue, which can be visualized as spontaneouslyCell 152, 570–583, January 31, 2013 ª2013 Elsevier Inc. 573
Figure 3. Bvht Regulates a Core Network of
Genes that Drive Cardiac Differentiation
(A) Heatmap representing hierarchical clustering of
all genes that displayed a 3-fold or greater differ-
ence in transcript levels in Bvht-depleted EBs
compared to controls at days 0, 3, 6, and 9.
(B) Significant gene ontology (GO) terms retrieved
by clusters G–I.
(C) Pearson correlation network of the EB time
course generated using the Spring-embedded
algorithm in Cytoscape. Genes in enriched GO
categories are represented in the network. A
sequence of cardiac transcription factors and
genes involved in myofibril organization were not
induced during EB differentiation in Bvht-depleted
cells. Nodes represent genes, and connections
represent correlation coefficient.
See also Figures S3, S4, and S5 and Table S3.contracting EBs during differentiation. In control cells, >25% of
EBs beat at day 11 of differentiation, compared to 5% of the
Bvht-depleted EBs (Figures 2C, S2D, and S2E). Consistent
with this observation, cardiac troponin T (cTnT), an integral com-
ponent of the contraction machinery in cardiac muscle, was
expressed at significantly lower levels in Bvht-depleted EBs
(Figures 2D and 2E). In contrast, cells depleted of AK085506,
an ESC-specific lncRNA not expressed in the heart, displayed
a similar proportion of contracting EBs (Figures 1B and S2F).
Examination of EB sections at day 12 of differentiation showed
a range of tissues, such as neural rosettes, gut endoderm, and
cartilage (Figure 2F). Together, these data suggest that Bvht is
not required for global ESC differentiation and may have specific
functions in cardiac commitment.574 Cell 152, 570–583, January 31, 2013 ª2013 Elsevier Inc.Braveheart Regulates the Core
Cardiovascular Gene Network
lncRNAs can act in cis to regulate expres-
sion of neighboring genes or in trans by
diverse mechanisms (Ørom and Shiekhat-
tar, 2011; Rinn and Chang, 2012). We first
analyzed the expression of neighboring
genes within a 100 kb window, which
included the convergent and overlapping
miR143/145 cluster on the opposite
strand (exons do not overlap) (Figure S3A).
Expression of neighboring protein-coding
genes was unaffected in Bvht-depleted
cells during ESC differentiation compared
to control cells; however, the pri-miRNA
was not properly expressed during the
time course (Figure S3B). It is likely that
lack of expression of the pri-miRNA is
due to depletion of cardiac cells in the
Bvht-depleted EBs rather than direct
regulation by Bvht. For example, miR143
and miR145 are typically transcribed
in cardiovascular cell types (Cordes
et al., 2009; Xin et al., 2009). Moreover,
miR143/145 knockout ESCs formed con-tracting, cTNT-positive EBs and showed clear differences in
gene expression patterns compared to Bvht-depleted cells
(Figures S3C–S3E and S4 and Table S2). Thus, these data indi-
cate that the Bvht phenotype is likely not a consequence of
failure to regulate closely neighboring genes in cis, including
the mir143/145 cluster.
We next reasoned that analysis of global gene expression
patterns during EB differentiation might reveal further clues
toward elucidating Bvht function. To this end, we analyzed
gene expression patterns at various time points by RNA-seq.
We found 548 differentially expressed genes in the Bvht-
depleted cells compared to controls (Figure 3A and Table S3).
These genes were clustered by expression pattern, yielding
several distinct clusters. Strikingly, genes in clusters that
displayed lower expression at later stages (i.e., clusters G–I)
showed enrichment for genes that function in heart and blood
vessel morphogenesis, heart and muscle system process, and
myofibril assembly (Figure 3B). In contrast, genes in clusters
that displayed higher expression in Bvht-depleted cells (i.e.,
clusters A–F) were not enriched for specific gene ontology
(GO) terms.
To gain further insights, we created a network diagram to illus-
trate how genes in the enriched GO categories changed in
expression over time by computing a Pearson correlation coeffi-
cient of expression between all pairs of genes (Figure 3C). Our
analysis revealed a complex network of transcription factors
that failed to activate during differentiation, including key regula-
tors of heart development, such as MesP1, Hand1, Hand2,
Nkx2.5, and Tbx20 as well as genes with roles in cardiomyocyte
structure and function, which have been implicated in cardiovas-
cular diseases (Bruneau, 2008; McCulley and Black, 2012).
Though a caveat of the EB assay is that it is difficult to distin-
guish subtle effects among related lineages, we observed that,
whereas expression of genes representing cardiovascular cell
types, including cardiomyocytes, vascular endothelium, and
smooth muscle, were significantly reduced, markers of paraxial
mesoderm, hematopoiesis, and endoderm were expressed at
normal or slightly elevated levels in Bvht-depleted EBs (Fig-
ure S5A). Moreover, Bvht-depleted cells displayed similar
morphology upon neuronal differentiation by addition of retinoic
acid and expressed similar levels of neural markers such asSox1
and Nestin compared to controls (Figure S5B and data not
shown). Together, these data suggest that Bvht specifically
promotes activation of a core gene regulatory network in trans
to direct cardiovascular cell fate.
Braveheart Functions Upstream of MesP1
MESP1 was among the earliest transcription factors in the gene
network that showed significantly lower expression in Bvht-
depleted EBs. MesP1 marks a common multipotent cardiovas-
cular progenitor that ultimately specifies all cell types of the heart
(Bondue et al., 2008; 2011; David et al., 2008; Lindsley et al.,
2008). To test whether Bvht and MesP1 function in a similar
pathway, we compared the differentially expressed genes in
our EB time course with those changed upon MesP1 induction
(Bondue et al., 2008). We observed a striking correlation among
genes that showed lower expression in Bvht-depleted cells and
higher expression upon MesP1 induction, denoted as group II
(p < 6 3 1062). Genes that showed higher expression in Bvht-
depleted cells and reduced expression upon MesP1 induction
also overlapped significantly and were denoted as group III
(p < 93 1045) (Figures 4A and 4B). Notably, group II genes func-
tion in transcriptional regulation, heart development, and tissue
morphogenesis and included many of the transcription factors
represented in the Bvht network (Figure 4C and Table S4). These
results suggest that Bvht depletion leads to failure to activate
a MESP1-driven gene expression program.
We expected that, if Bvht functions upstream of MesP1, then
forced expression ofMesP1 should rescue the depletion pheno-
type. We employed a doxycycline-inducible MesP1 mESC line
(Bondue et al., 2008) and induced expression at day 2 of EB
differentiation in Bvht-depleted and control cells.MesP1 cardio-vascular progenitors comprise a very small proportion of cell
types in early stage EBs, and induction at this time point leads
to expansion of the cardiogenic population (Bondue et al.,
2008; Lindsley et al., 2008). Notably, MesP1 induction led to an
increase in contracting EBs in both control and Bvht-depleted
cells (Figure 4D). We also found that Bvht levels were 10-fold
higher in MESP1 population compared to negative cells using
a mESC line that harbored GFP under the control of the MesP1
promoter (Bondue et al., 2011) (Figure 4E). Together, these
data suggest that Bvht functions upstream ofMesP1 as a poten-
tial regulator of cardiovascular fate.
Braveheart Promotes Cardiac Cell Fate from Nascent
Mesoderm
To further dissect Bvht function in the cardiovascular lineage, we
employed a directed in vitro cardiomyocyte (CM) differentiation
assay that permits isolation of cell populations at well-defined
stages (ESCs, precardiac mesoderm [MES], cardiac progenitors
[CPs], and CMs) (Kattman et al., 2011; Wamstad et al., 2012)
(Figure 5A). Using this assay, we observed that Bvht-depleted
EBs were smaller and displayed an irregular shape at day 4
(MES) and failed to form an adherent monolayer at day 5.3
(CP) compared to controls (Figure 5B, middle and right panels).
In contrast, no visible change in morphology was apparent at
day 2, a time point that precedes the addition of cardiac growth
factors (Figure 5B, left). We also found an increase in apoptosis
but no change in cell-cycle kinetics at day 4 in Bvht-depleted
cells, whereas day 2 cells showed no difference (Figures 5C
and S6A). Notably, shRNA-mediated depletion of MesP1
showed similar effects to Bvht depletion, and Bvht overexpres-
sion led to an increase in the levels of cardiac genes, including
MesP1, during CM differentiation (Figures S6B and S6C and
data not shown).
Brachyury (T) and Eomesodermin (Eomes), transcription fac-
tors expressed in the primitive streak, have critical roles in
mesoderm induction and regulateMesP1 expression by directly
binding to its promoter (Costello et al., 2011; David et al., 2011).
Though T and Eomes were expressed normally or at elevated
levels at day 4 in Bvht-depleted and controls cells, both factors
displayed higher levels in day 5.3Bvht-depleted cells (Figure 5D).
Notably, expression of core cardiac transcription factors, in-
cluding MesP1, failed to induce at day 4 and day 5.3 in Bvht-de-
pleted cells despite expression of T and Eomes (Figures 5E and
5F). Similarly, expression of cell surface markers of early cardiac
identity (i.e., PdgfRa and Flk-1) was lower in Bvht-depleted cells
(Figure 5G). Together, PdgfRa and Flk-1 define an early multipo-
tent cardiovascular progenitor population (marked by MesP1),
and their coexpression enhances cardiogenic potential (Kattman
et al., 2006; Yang et al., 2008). Conversely, Fgf8 andMixl1 levels
were elevated in Bvht-depleted cells during CM differentiation,
consistent with a reciprocal increase in hematopoietic markers
upon loss of cardiac potential (Lim et al., 2009; Simo˜es et al.,
2011) (Figure S6D).
MESP1 also regulates EMT genes whose expression is critical
for migration of precardiac cells during gastrulation (Lindsley
et al., 2008). We found that expression of EMT genes such as
Snai1 and Snai2, as well as Twist1 and Twist2 (Yang et al.,
2004), was not induced at day 5.3 in Bvht-depleted cellsCell 152, 570–583, January 31, 2013 ª2013 Elsevier Inc. 575
Figure 4. Bvht Functions Upstream of MesP1
(A) Gene expression comparison between Bvht depletion and Mesp1 induction.
(B) The overlap is highly significant for quadrants II and III as measured by hypergeometric test with Benjamini correction. Genes in quadrant II failed to activate in
Bvht-depleted cells and are expressed at higher levels upon Mesp1 induction, whereas quadrant III genes displayed the opposite expression pattern.
(C) Enriched GO terms based on genes in quadrant II.
(D) Forced MesP1 expression can rescue the contraction defect in Bvht-depleted EBs. Contracting EBs were counted at day 11 (n > 100).
(E) Bvht is enriched in cells expressing a GFP reporter under the control of the Mesp1 promoter (pMESP1-GFP) compared to GFP-negative cells as analyzed by
FACS at day 5 (peak of MesP1 expression) of EB differentiation followed by qRT-PCR.
Experiments were performed in triplicate, and error bars represent SD in all panels. **p < 0.01 and *p < 0.05 by two-tailed Student’s t test. See also Table S4.compared to controls (Figure 5H). Snai1 and Snai2 repress
E-cadherin, and the switch from E-cadherin to N-cadherin
expression is a hallmark of EMT (Lim and Thiery, 2012). Notably,
E-cadherin levels remained high, and N-cadherin was not ex-
pressed in Bvht-depleted cells (Figure 5H). Together, these
results indicate that Bvht is required at a critical time during
differentiation when cardiac cells are specified from nascent
mesoderm.
Our observations suggest that Bvht functions in the same
pathway as MesP1 in a cell-autonomous manner to regulate
a core cardiac gene network. To test this idea, we generated
ESC lines that harbored either the shBvht or shControl vector
additionally marked with GFP or mCherry to allow us to track
each population. Equal numbers of shControl-mCherry and
shBvht-GFP ESCs were combined and analyzed by fluores-
cence-activated cell sorting FACS during CM differentiation.
Although the proportion of marked cells was similar in ESCs
and at day 2, we observed a dramatic overrepresentation of
shControl cells at days 4 and 5.3, indicating that Bvht-depleted576 Cell 152, 570–583, January 31, 2013 ª2013 Elsevier Inc.cells cannot efficiently contribute to cardiac cell types (Figure 5I).
Similar results were obtained using reciprocal markers (Fig-
ure S6E). Notably, cardiac genes such as Gata4, Nkx2.5, Tbx5,
and Isl1were expressed at normal levels at day 5.3 (Figure S6F),
indicating that control cells could differentiate properly in the
presence of Bvht-depleted cells. Thus, our results support a
cell-autonomous role for Bvht in the transcriptional control of
cardiac cell fate.
Braveheart Interacts with SUZ12, a Core Component
of PRC2
Some lncRNAs are thought to act through RNA-protein interac-
tions to effect gene expression by diversemechanisms (Rinn and
Chang, 2012). Because T and EOMES have been shown to bind
to the MesP1 promoter and to regulate its expression (David
et al., 2011; Costello et al., 2011), we first tested whetherBvht in-
teracted with T or EOMES to mediate their binding at the MesP1
promoter. We performed RNA immunoprecipitation (RIP) using
antibodies against T or EOMES; however, we failed to detect
a specific interaction with Bvht (Figure S7A). We also did not
detect changes in the binding of T to the MesP1 promoter
by chromatin immunoprecipitation (ChIP) followed by qPCR
(Figure S7B and Supplemental Information). Thus, it is unlikely
that Bvht directly regulates T or EOMES to control MesP1
activation.
lncRNAs can act as molecular scaffolds by interacting with
chromatin-modifying complexes (Guttman et al., 2011; Tsai
et al., 2010). Using in vitro biotin-RNA pull-down, we detected
a specific interaction between Bvht and SUZ12 in ESCs; how-
ever, other factors thought to bind lncRNAs, including hnRNPK,
SNW1,RING1b,OCT4, BRG1, andMLL1, did not showa specific
interaction (Figure 6A). These data were confirmed by RIP using
SUZ12-specific antibodies (data not shown). SUZ12 is a core
subunit of PRC2, a complex that catalyzes trimethylation of
histone H3 lysine 27 (H3K27me3) and mediates transcriptional
repression (Surface et al., 2010). A number of lncRNAs have
been shown to interact with PRC2 to regulate target gene ex-
pression (Wang and Chang, 2011). We then constructed a series
of Bvht deletions and found several regions of the transcript that
were required for this interaction (Figure 6B), suggesting that
Bvht directly interacts with PRC2.
Next, we tested whether Bvht interacted with SUZ12 during
CM differentiation. Similar to ESCs, we found that SUZ12 inter-
acted with Bvht by RIP at day 5.3 cells (Figure 6C). We chose
to analyze day 5.3 cells because these cells comprise a largely
homogenous population of >70% NKX2.5-positive cells and
because Bvht is enriched in this population (Figure S7C). Many
of the cardiac genes that failed to activate in Bvht-depleted cells
at day 5.3 are known polycomb targets in ESCs (Boyer et al.,
2006). These genes are poised for activation in ESCs, as indi-
cated by their bivalent chromatin marks (H3K27me3 and
H3K4me3) (Bernstein et al., 2006), and differentiation toward
specific lineages requires the selective loss of PRC2 at subsets
of genes. We found that, in Bvht-depleted cells, SUZ12 levels re-
mained high at the promoters of critical genes in the cardiovas-
cular network, including MesP1, Gata6, Hand1, Hand2, and
Nkx2.5, compared to control cells as measured by ChIP-qPCR
(Figure 6D). In contrast, SUZ12 levels were lower at T and
Eomes, consistent with their higher expression at day 5.3 in
Bvht-depleted cells. SUZ12 levels were equivalent in both
Bvht-depleted and control cells (Figure S7D). We also found
that H3K27me3 levels paralleled SUZ12 enrichment in both
Bvht-depleted and control cells. Notably, cardiac genes main-
tained their bivalent status at day 5.3 (Figures S7E and S7F),
consistent with a failure to activate the cardiac program. Though
our data do not distinguish between a direct or indirect mecha-
nism, these results along with the demonstrated interaction
between SUZ12 and Bvht suggest that Bvht functions, in part,
with PRC2 to regulate cardiac commitment.
Braveheart Is Necessary for Maintenance of Cardiac
Fate in Neonatal CMs
Our data show that Bvht is required for the commitment of
ESCs toward a cardiac fate. Because we detected expression
of Bvht in the adult mouse heart (Figure 1B), we investigated
whether Bvht functions in later stages of differentiation. We
analyzed the effect of Bvht depletion in primary murine neonatalventricular cardiomyocyte (nCMs) cultures, a model that has
been used extensively for investigating drug and injury re-
sponses (Louch et al., 2011). In brief, nCMs were isolated from
the newborn heart, a stage when myocytes display plasticity
both in vivo and in vitro, as evidenced by increased levels of early
cardiac markers such as Gata4 and Nkx2.5 (Porrello et al., 2011;
Zhang et al., 2010). Within days of isolation, nCMs are able to
organize into myofibrils, forming sheets of beating cardiomyo-
cytes in explant cultures. Thus, neonatal cardiomyocytes repre-
sent an ex vivo model in which to test the role of Bvht in modu-
lating cardiac cell fate in the heart.
nCMs were infected 1 day after explant with Bvht or control
shRNA lentiviruses harboring a GFP marker. We found that
Bvht-depleted nCMs as marked by GFP displayed unevenly
distributed and irregularly bundled myofibrils after 5 days in
culture compared to control cells as evidenced by cTNT stain-
ing (Figure 7A). Consistent with this observation, the overall
cell surface area of individual GFP-positive nCMs was signifi-
cantly smaller (Figure 7B), indicating that nCM structure is dis-
rupted in Bvht-depleted cells (Figure 7C). Moreover, structural
genes that were not properly activated in Bvht-depleted EBs,
including a- and b-MHC and Sma, displayed lower expression
in the Bvht-depleted nCMs compared to controls (Figure 7D),
whereas early cardiac markers Gata4 and Nkx2.5 displayed
higher expression (Figure 7E). Notably, genes involved in EMT
such as Snai and Twist members, as well as Vimentin, showed
lower expression in Bvht-depleted nCMs (Figure 7F). These
data suggest that Bvht plays a critical role in promoting cardiac
gene expression programs and tissue remodeling in the devel-
oping heart.
DISCUSSION
Dynamic regulation of gene expression programs is critical for
cell fate transitions during lineage commitment, and faulty regu-
lation can lead to developmental failure and disease. Heart
development is a multistep process regulated by a network of
transcription factors, and disruption of transcriptional networks
leads to congenital heart disease (Bruneau, 2008; McCulley
and Black, 2012; Olson, 2006; Srivastava, 2006). Though many
of the genetic factors that govern heart development are known,
we hypothesized that lncRNAsmay represent an additional layer
of regulation. Here, we identify Braveheart as a critical regulator
of cardiovascular commitment from nascent mesoderm, repre-
senting the first example of a lncRNA with potential implications
in cardiovascular development.
The temporal activation of a core transcription factor network
establishes the plan for a primitive heart. The genes in this
network are highly conserved during evolution, whereas the
formation of more complex and species-specific substructures
is likely a consequence of evolution of species-specific regula-
tors. Analysis of sequence conservation and potential transcripts
in syntenic regions in the rat and human genomes did not identify
a Bvht homolog. The lack of conservation is likely due to both
weak selective pressure on the primary sequence of lncRNAs
and rapid gain and loss of entire lncRNA genes. For example,
noncoding genes such as Xist and Neat1 have undergone rapid
sequence evolution while preserving their functional rolesCell 152, 570–583, January 31, 2013 ª2013 Elsevier Inc. 577
Figure 5. Bvht Is Necessary for the Transition from Nascent to Cardiac Mesoderm In Vitro
(A) ESCs were differentiated into beating cardiomyocytes (CM) and progress through precardiac mesoderm (MES) and cardiac progenitor (CP) stages by
sequential addition of cytokines.
(B) Bvht-depleted EBs were smaller than controls at day 4 and failed to attach and organize into a monolayer at day 5.3. Scale bar, 65 mm.
(C) Bvht-depleted cells showed increased levels of apoptosis at day 4 as indicated by quantification of annexin-V-positive cells, whereas no significant difference
was observed at day 2.
(D) Brachyury and Eomes levels remained high at day 5.3 compared to control as measured by qRT-PCR.
(E and F) Core cardiac transcription factors displayed lower expression at days 4 (E) and 5.3 (F) in Bvht-depleted cells compared to control.
(G) Expression of cell surface markers PdgfRa and Flk-1 was significantly decreased upon Bvht depletion at days 4 and 5.3 compared to control.
(H) EMT genes displayed altered expression patterns in Bvht-depleted cells at day 5.3 as measured by qRT-PCR. Values for shControl samples were normalized
to 1 for each individual time point.
(legend continued on next page)
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Figure 6. BvhtDirectly Interactswith SUZ12
during CM Differentiation
(A) Biotin-RNA pull-downs using full-length Bvht
transcript in nuclear ESC extracts showed specific
binding to SUZ12.
(B) Deletion analysis of Bvht transcript showed
that 50 and 30 regions were required for interaction
with SUZ12.
(C) Bvht interacts with SUZ12 in day 5.3 cells
(CP stage) as determined by RIP using SUZ12
antibody.
(D) ChIP using SUZ12 antibody showed higher
levels at promoter regions of cardiac and EMT
genes in Bvht-depleted day 5.3 cells compared
to controls, whereas no significant changes were
observed in genes expressed in other lineages
(e.g., Sox1 and Sox17).
Experiments were performed in triplicate, and
error bars represent SD in all panels. **p < 0.01 and
*p < 0.05 by two-tailed Student’s t test. See also
Figure S7.(Clemson et al., 2009; Nesterova et al., 2001). Increasing
evidence also suggests that lncRNAs are largely species
specific, with many transcripts arising from the primate lineage
(Derrien et al., 2012). Thus, Bvht appears to represent a noncon-
served lineage-specific lncRNA; however, we expect that other
species with a defined circulatory system may have evolved
lncRNAs with similar functions.
Bvht Is an Upstream Regulator of Cardiovascular
Commitment
Our work suggests that Bvht functions upstream of and in the
same genetic pathway as MesP1 as a permissive factor for
cardiac commitment during ESC differentiation. MesP1 expres-
sion can specify all cell types of the cardiovascular lineage (Bon-
due et al., 2008; Lindsley et al., 2008), and its expression is
sufficient to transdifferentiate dermal fibroblasts into cardiac
progenitors along with the transcription factor ETS2 (Islas
et al., 2012), indicating that Bvht may also be critical for forward
programming and reprogramming toward a cardiovascular fate.
EMT is critical for gastrulation and morphogenetic movements
throughout development, including during heart formation (Lim
and Thiery, 2012; von Gise and Pu, 2012). EMT is equally critical
for in vitro differentiation of stem cells and somatic cell reprog-
ramming, during which cells transition through multiple stages
(Esteban et al., 2012). Snai and Twist, well-characterized regula-
tors of EMT, are downstream targets of MESP1 and have been
implicated in various aspects of heart and vascular development(I) Equal numbers of mCherry-shControl and GFP-shBvht1 cells were mixed and subjected to cardiac differen
was observed at days 4 and 5.3, whereas cells cultured in ESC conditions maintain equal distribution.
Error bars represent SD of three replicates within one representative experiment. **p < 0.01 and *p
Figure S6.
Cell 152, 570–583(Lindsley et al., 2008). We found that Bvht
was necessary for expression of an EMT
gene network, including Snai and Twist
members in CM differentiation and in
nCMs, indicating that Bvht may alsoregulate cardiac commitment through organization of a func-
tional tissue.
BvhtMay Function with PRC2 to Regulate Cardiac Gene
Expression Program
Epigenetic regulation plays an important role in development of
the cardiovascular system (Chang and Bruneau, 2012). Recent
studies have shown that Ezh2, the catalytic component of
PRC2, is necessary for repression of the progenitor program
during cardiac differentiation and for proper spatiotemporal
regulation of cardiac gene expression (Delgado-Olguı´n et al.,
2012; He et al., 2012). We found that Bvht directly interacted
with PRC2 through SUZ12, a core component of the complex,
at several stages during CM differentiation. Notably, SUZ12
and its associated modification H3K27me3 were enriched at
promoters of cardiac genes, including MesP1 in Bvht-depleted
cells. Cardiac genes also remained bivalent in Bvht-depleted
cells, similar to their configuration in ESCs and consistent
with a failure to activate the cardiac program. Although we
cannot yet distinguish between a direct or indirect role for
Bvht at these loci, one model is that Bvht binds SUZ12 and
competes for PRC2 binding at target sites during the
transition from nascent to cardiac mesoderm, leading to acti-
vation of the cardiac program. Alternatively, Bvht may recruit
PRC2 to a repressor of the cardiac program, where loss of
Bvht would fail to silence the repressor. Though further studies
will be required to fully elucidate the mechanism of Bvhttiation. A dramatic decrease in Bvht-depleted cells
< 0.05 by two-tailed Student’s t test. See also
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Figure 7. Bvht Is Required to Maintain Cardiac Fate in Neonatal Cardiomyocytes
(A) Bvht-depleted or control nCMs were identified by the presence of a GFP reporter in the shRNA vector. Myofibrils clustered together in GFP-positive control
cells, whereas Bvht depletion resulted in disorganized cardiac myofibril bundles. Myofibrils were visualized by IF using an antibody against cTnT (red) and GFP
(green). Nuclei (blue) were stained with Hoechst. Scale bars, 20 mm.
(B) Bvht-depleted nCMs were overall smaller than controls as assessed by the surface area of GFP-positive versus control cells (n > 100).
(C) Global levels of Bvht (qRT-PCR) in control and Bvht-depleted nCM cultures.
(D) Reduced expression of sarcomeric and myofibril components in Bvht-depleted nCMs as measured by qRT-PCR.
(E) Expression (qRT-PCR) of transcription factors involved in early cardiogenesis was increased in Bvht-depleted cells.
(F) Factors involved in EMT were expressed at lower levels in Bvht-depleted cells.
Experiments were performed in triplicate, and error bars represent SD in all panels. **p < 0.01 and *p < 0.05 by ANOVA and Dunnett’s test.function, our work suggests that Bvht mediates cardiac
commitment, in part, by epigenetic regulation of gene expres-
sion programs.
Implications ofBvht in Cardiovascular Development and
Disease
Cardiovascular disease is one of the most common causes
of death, yet the mammalian heart has limited regenerative
capacity. Thus, a detailed understanding of the pathways in-
volved in cardiogenesis and particularly factors dictating com-580 Cell 152, 570–583, January 31, 2013 ª2013 Elsevier Inc.mitment will be instrumental for recapitulating these processes
for regenerative therapy. Stem cell models and the generation
of specific cell types in vitro offer a potential avenue for studying
diseases in a dish and ultimately for transplantation therapy (Bur-
ridge et al., 2012). Thus, our finding that Bvht is required for
progression of cardiac commitment suggests that lncRNAs
represent a class of molecular modulators that can direct cell
fate. Direct comparisons of cardiovascular-associated lncRNAs
across species should contribute further insights into how these
regulators are integrated into the gene regulatory networks that
drive cardiogenesis and may also provide important clues into
the evolution of this complex organ. Moreover, our data suggest
that lncRNAs may represent undiscoverd disease loci that, in
some cases, may be identifiable by genome-wide association
studies (GWAS) (Mattick, 2009; Schonrock et al., 2012). For
example, the human lncRNA ANRIL has been associated with
a locus implicated in cardiovascular disease (Congrains et al.,
2012). In addition, humanMIAT was identified as a lncRNA asso-
ciated with increased risk of myocardial infarction (Ishii et al.,
2006). Thus, we anticipate that future studies to identify addi-
tional lncRNAs with roles in cardiac function will lead to a better
understanding of heart development and will inform strategies
for cardiac repair.
EXPERIMENTAL PROCEDURES
Detailed experimental and analysis methods can be found in the Supplemental
Information.
ESC Lines and Growth Conditions
E14 (ola/129), V6.5 (SvJae129/C57BL/6), MesP1-GFP, A2lox-MesP1,
NKX2.5-GFP, and miR-143/145 ESCs were cultured on irradiated MEFs using
standard conditions.
Generation of ESC Lines
shRNA-Mediated Depletion of lncRNAs
shRNAs directed against Bvht, Mesp1, and control hairpins were cloned
into pLKO.1 vector. Production of lentiviral particles and transduction of
ESCs was performed according to protocols from The RNAi Consortium
(http://www.broadinstitute.org/rnai/trc).
Bvht Overexpression
Full-length Bvht cDNAwas cloned into pSLIK vector, and transgenic cells were
generated as described above.
ESC Differentiation
Embryoid Body Formation
ESCs were preplated to remove feeders, diluted to 100,000 cells/ml in com-
plete growth medium lacking LIF, and plated on low-attachment cell culture
plates.
Cardiomyocyte Differentiation
Directed differentiations and analysis were performed as described (Wamstad
et al., 2012).
Identification of Candidate lncRNAs
Expression data from ESCs (V6.5 and E14) (this study) and adult tissues (Mor-
tazavi et al., 2008) were collated using two annotations (Flicek et al., 2011;
Guttman et al., 2010) to define a set of murine lncRNAs. Candidate lncRNAs
were identified by a stringent set of criteria outlined in the Supplemental
Information.
Genomic Analysis of Braveheart
50 and 30 RACE was performed using FirstChoice RLM-RACE kit (Ambion) on
ESC RNA, and products were cloned using TOPO TA cloning kit (Invitrogen).
See Table S5 for primer sequences.
Preparation of RNA Sequencing Libraries and Analysis
RNA-seq was performed as described (Wamstad et al., 2012), and reads
were mapped using Tophat/Bowtie. Isoform identification and quantification
were performed using Cufflinks. RNA-seq quality control metrics are listed in
Table S6.
Gene Coexpression Network
The cascade network of coexpression was generated based on the
Pearson correlations of the RNA-seq expression profiles, which aredescribed by log2-fold change between Bvht and control knockdown cells.
The layout of the network was created using the Spring-Embedded layout
algorithm (Cytoscape plug-in), as described in the Extended Experimental
Procedures.
Competition Assay/Cell Autonomy
GFP and mCherry coding sequences were cloned into plKO.1 vector contain-
ing control and Bvht hairpins (Table S5). Cells were isolated by FACS 4 days
after infection to select for those expressing the fluorescent proteins. Equal
numbers of ESCs were mixed, analyzed by FACS, and then plated under car-
diomyocyte differentiation or ESC culture conditions. Cells were analyzed by
FACS at various time points to determine the proportion of each fluorescently
marked population.
RNA Immunoprecipitation
Native RIP was performed as described (Rinn et al., 2007). Antibodies are
listed in the Supplemental Information.
Chromatin Immunoprecipitation
The ChIP protocol has been adapted from previous studies (Creyghton
et al., 2008). Antibodies are listed in the Supplemental Information. ChIP-en-
riched DNA was quantified by qRT-PCR. Primers are listed in Table S5.
Isolation and Manipulation of Primary Mouse Neonatal
Cardiomyocytes
Murine neonatal cardiomyocytes (nCMs) were isolated from C57B6 mice
within the first 24 hr after birth. A detailed protocol can be found in the
Extended Experimental Procedures.
ACCESSION NUMBERS
All RNA-sequencing data generated during the course of this study, including
raw reads and analysis files, have been deposited to GEO under the accession
ID GSE39656.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and six tables and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2013.01.003.
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